The loss of function of BRCA1/2 sensitizes cells to poly (ADP-ribose) polymerase (PARP) inhibitors [2, 11, 12], and findings from clinical trials have resulted in the PARP inhibitor olaparib being approved for maintenance treatment of women with BRCA1- or BRCA2-mutated high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer [11, 12]. Here, BRCA1 is linked to ovarian serous adenocarcinoma.